VolitionRx (NYSE:VNRX - Get Free Report)'s stock had its "buy" rating restated by investment analysts at D. Boral Capital in a research note issued on Thursday,Benzinga reports. They presently have a $5.00 price target on the stock.
A number of other analysts also recently issued reports on the stock. Benchmark reissued a "hold" rating on shares of VolitionRx in a report on Friday, November 22nd. StockNews.com started coverage on VolitionRx in a research note on Thursday. They issued a "sell" rating for the company.
Read Our Latest Report on VNRX
VolitionRx Stock Down 0.4 %
Shares of NYSE VNRX traded down $0.00 during mid-day trading on Thursday, reaching $0.55. 115,583 shares of the company were exchanged, compared to its average volume of 178,468. VolitionRx has a twelve month low of $0.43 and a twelve month high of $1.02. The stock has a market capitalization of $50.78 million, a P/E ratio of -1.52 and a beta of 1.09. The company's 50-day simple moving average is $0.60 and its 200-day simple moving average is $0.64.
Institutional Inflows and Outflows
A number of hedge funds have recently added to or reduced their stakes in the company. Geode Capital Management LLC lifted its stake in VolitionRx by 15.1% during the third quarter. Geode Capital Management LLC now owns 730,448 shares of the company's stock worth $439,000 after purchasing an additional 95,900 shares during the last quarter. Two Sigma Securities LLC acquired a new stake in VolitionRx in the fourth quarter valued at about $29,000. Northern Trust Corp raised its stake in VolitionRx by 32.0% during the fourth quarter. Northern Trust Corp now owns 117,875 shares of the company's stock worth $71,000 after acquiring an additional 28,579 shares in the last quarter. Lagoda Investment Management L.P. increased its position in VolitionRx by 24.3% during the 4th quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company's stock worth $4,546,000 after purchasing an additional 1,481,000 shares in the last quarter. Finally, Millennium Management LLC bought a new position in shares of VolitionRx in the 4th quarter valued at $36,000. 8.09% of the stock is owned by institutional investors.
VolitionRx Company Profile
(
Get Free Report)
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.
See Also
Before you consider VolitionRx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and VolitionRx wasn't on the list.
While VolitionRx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
